Literature DB >> 15123665

Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion.

Mikael Björklund1, Pia Heikkilä, Erkki Koivunen.   

Abstract

Migration of invasive cells appears to be dependent on matrix metalloproteinases (MMPs) anchored on the cell surface through integrins. We have previously demonstrated an interaction between the integrin alpha-subunit I domain and the catalytic domain of MMP-9. We now show that there is also an interaction between the integrin beta subunit and MMP-9. Using phage display, we have developed MMP-9 inhibitors that bind either to the MMP-9 catalytic domain, the collagen binding domain, or the C-terminal hemopexin-like domain. The C-terminal domain-binding peptide mimics an activation epitope in the stalk of the integrin beta chain and inhibits the association of MMP-9 C-terminal domain with alpha(V)beta(5) integrin. Unlike other MMP-9 binding peptides, it does not directly inhibit catalytic activity of MMP-9, but still prevents proenzyme activation and cell migration in vitro and tumor xenograft growth in vivo. We also find an association between MMP-9 and urokinase-plasminogen activator receptor and find that urokinase-plasminogen activator receptor is cleaved by MMP-9. Collectively, we have defined molecular details for several interactions mediated by the different MMP-9 domains.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15123665     DOI: 10.1074/jbc.M401601200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

Review 1.  Peripheral membrane associations of matrix metalloproteinases.

Authors:  Steven R Van Doren; Tara C Marcink; Rama K Koppisetti; Alexander Jurkevich; Yan G Fulcher
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2017-04-23       Impact factor: 4.739

2.  A 17-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds α4β1 integrin and inhibits MMP-9-induced functions in chronic lymphocytic leukemia B cells.

Authors:  Estefanía Ugarte-Berzal; Elvira Bailón; Irene Amigo-Jiménez; Cidonia L Vituri; Mercedes Hernández del Cerro; María José Terol; Juan P Albar; Germán Rivas; José A García-Marco; Angeles García-Pardo
Journal:  J Biol Chem       Date:  2012-06-22       Impact factor: 5.157

3.  Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9.

Authors:  Antoine Dufour; Nicole S Sampson; Jian Li; Cem Kuscu; Robert C Rizzo; Jennifer L Deleon; Jizu Zhi; Nadia Jaber; Eric Liu; Stanley Zucker; Jian Cao
Journal:  Cancer Res       Date:  2011-06-06       Impact factor: 12.701

4.  Computational identification and analysis of early diagnostic biomarkers for kidney cancer.

Authors:  Tang Tang; Xiaoyan Du; Xiaoyi Zhang; Wenling Niu; Chunhua Li; Jianjun Tan
Journal:  J Hum Genet       Date:  2019-07-26       Impact factor: 3.172

5.  Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases.

Authors:  Janet C Reid; Admire Matsika; Claire M Davies; Yaowu He; Amy Broomfield; Nigel C Bennett; Viktor Magdolen; Bhuvana Srinivasan; Judith A Clements; John D Hooper
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

6.  Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation.

Authors:  Robert H Scannevin; Richard Alexander; Tara Mezzasalma Haarlander; Sharon L Burke; Monica Singer; Cuifen Huo; Yue-Mei Zhang; Diane Maguire; John Spurlino; Ingrid Deckman; Karen I Carroll; Frank Lewandowski; Eric Devine; Keli Dzordzorme; Brett Tounge; Cindy Milligan; Shariff Bayoumy; Robyn Williams; Celine Schalk-Hihi; Kristi Leonard; Paul Jackson; Matthew Todd; Lawrence C Kuo; Kenneth J Rhodes
Journal:  J Biol Chem       Date:  2017-08-31       Impact factor: 5.157

7.  Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway.

Authors:  Veronica C Ardi; Philippe E Van den Steen; Ghislain Opdenakker; Bernhard Schweighofer; Elena I Deryugina; James P Quigley
Journal:  J Biol Chem       Date:  2009-07-16       Impact factor: 5.157

8.  Identification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screening.

Authors:  Ludovic Bannwarth; Allison B Goldberg; Catherine Chen; Benjamin E Turk
Journal:  Chem Biol       Date:  2012-07-27

9.  Tumoral and macrophage uPAR and MMP-9 contribute to the invasiveness of B16 murine melanoma cells.

Authors:  Chiara Marconi; Francesca Bianchini; Antonella Mannini; Gabriele Mugnai; Salvatore Ruggieri; Lido Calorini
Journal:  Clin Exp Metastasis       Date:  2007-12-11       Impact factor: 5.150

10.  Role of leukemia cell invadosome in extramedullary infiltration.

Authors:  Michael Stefanidakis; Katja Karjalainen; Diana E Jaalouk; Carl G Gahmberg; Susan O'Brien; Renata Pasqualini; Wadih Arap; Erkki Koivunen
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.